Nanobiotix Presents Results of NBTXR3 (PEP503) in P-Ib/II Study for Rectal Cancer at ASCO-GI 2021
Bristol-Myers Squibb to Divest Celgene’s Otezla (apremilast) to Gain the US FTC’s Approval on Celgene Acquisition
Bristol-Myers Squibb to Divest Celgene’s Otezla (apremilast) to Gain the US FTC’s Approval on Celgene Acquisition
Shots:
- BMS plans to divest Otezla to address US Federal Trade Commission concern to close pending Celgene acquisition for $74B more quickly
- In Jan’2019, BMS announced to acquire Celgene with its expected closing of the transaction in H2’19 or H1’20. The divestiture of Otezla will accelerate BMS post-closing deleveraging plans
- Otezla is a PDE4 inhibitor, approved to treat moderate to severe plaque psoriasis and has generated a revenue of $1.6B in 2018
Click here to read full press release/ article | Ref: BMS | Image: SPJ News
